Followers | 145 |
Posts | 27565 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Monday, July 17, 2023 8:24:02 AM
https://finance.yahoo.com/news/icecure-medical-expands-distribution-prosense-120000916.html
ProSense has CE mark of regulatory approval in the European Union
Initial purchase of 2 ProSense Systems plus disposable cryoprobes and introducers
CAESAREA, Israel, July 17, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has entered a non-exclusive distribution agreement with Medicinália Cormédica – MC Medical, Lda. ("MC Medical"), the largest distributor of third-party medical devices in Portugal and a subsidiary of Barcelona, Spain based Werfen, S.A., a world leader in specialized diagnostics operating in 30 countries. Another Werfen, S.A. company, Izasa Scientific, is a ProSense distributor in Spain. This agreement with MC Medical further expands the distribution of ProSense in Europe where the system has the European Union's CE mark of regulatory approval.
Initial purchases by MC Medical include two ProSense consoles, along with disposable cryoprobes and introducers. Healthcare professionals in Portugal will now be able to perform precise and minimally invasive cryoablation procedures for indications including malignant and benign tissue of the breast, kidney, liver, lung, and bone, as well as for palliative interventions.
"We are very pleased to partner with MC Medical to expand the availability of ProSense cryoablation into Portugal," stated Eyal Shamir, CEO of IceCure Medical. "Their dedication to quality and innovation in healthcare aligns with our aim to improve patient outcomes through minimally invasive cryoablation procedures. As the largest distributor of third-party medical devices in Portugal with a staff of 72 professionals across sales, service and support, MC Medical is extremely well equipped to drive ProSense adoption throughout Portugal."
"There is a growing interest in minimally invasive cryoablation procedures in Portugal driven by favorable patient outcomes and healthcare economics. IceCure's ProSense is the best choice for cryoablation systems on the market today. Backed by clinical data and regulatory approvals, ProSense is a system that we believe will gain rapid and wide market traction in Portugal," said Diogo Lima, General Manager of MC Medical.
About Medicinália Cormédica - MC Medical, Lda
Medicinália Cormédica- MC Medical, Lda. is a leading business partner for Medical Device distribution in Portugal with over 60 years of history and a strong track record for introducing disruptive technologies and clinical innovation. They operate with exclusivity rights to market and sell a comprehensive product portfolio from a wide range of manufacturers, with a steady footprint and expertise in areas such as anesthesia, operating rooms, interventional cardiology, cardiothoracic surgery, general surgery, vascular surgery, intensive care, homecare - ostomy, neurovascular intervention, obstetrics, oncology, ENT, biomedical simulation, wound treatment, emergency medicine, and urology.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) (TASE: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.
Recent ICCM News
- IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer • PR Newswire (US) • 04/15/2024 12:35:00 PM
- IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance • PR Newswire (US) • 04/03/2024 12:30:00 PM
- U.S. Futures Dip in Pre-Market, May WTI and June Brent Crude Prices Edge Higher • IH Market News • 04/03/2024 11:11:59 AM
- IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes • PR Newswire (US) • 04/02/2024 12:30:00 PM
- IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 • PR Newswire (US) • 03/27/2024 12:30:00 PM
- IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy • PR Newswire (US) • 03/19/2024 12:30:00 PM
- IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes • PR Newswire (US) • 03/12/2024 12:30:00 PM
- IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference • PR Newswire (US) • 03/07/2024 01:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2024 01:35:29 PM
- IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024 • PR Newswire (US) • 03/04/2024 01:30:00 PM
- Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop • PR Newswire (US) • 02/27/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/26/2024 01:15:29 PM
- Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer • PR Newswire (US) • 02/26/2024 01:00:00 PM
- IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan • PR Newswire (US) • 02/15/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/30/2024 01:15:02 PM
- U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer • PR Newswire (US) • 01/30/2024 01:00:00 PM
- IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class • PR Newswire (US) • 01/29/2024 01:00:00 PM
- IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation • PR Newswire (US) • 01/16/2024 01:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/12/2024 09:39:23 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/12/2024 09:18:50 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/12/2024 09:10:20 PM
- IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule • GlobeNewswire Inc. • 01/12/2024 09:05:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/10/2024 01:15:26 PM
- IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results • PR Newswire (US) • 01/10/2024 01:00:00 PM
- New Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response • PR Newswire (US) • 01/03/2024 01:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM